Amedica announces collaboration with Celling Biosciences to enhance spinal fusion devices

Amedica Corporation announced a collaboration with Celling Biosciences for the research and development of enhanced biological implants, according to a company press release.

A recent in vivo study demonstrated the silicon nitride composition developed by Amedica performed better than polyetheretherketone (PEEK) with regard to attachment testing of mesenchymal stem cells, the release noted. When initial research began, Celling Biosciences determined mesenchymal stem cells can be optimized with silicon nitride use compared with the use of PEEK and titanium biomaterials.

With this research now completed, Celling Biosciences will be able to translate these findings and use the technology for clinical trials in spinal and orthopedics applications, according to the release.

“The initial findings by Celling Biosciences further validate the unique benefits of our medical-grade silicon nitride technology platform,” B. Sonny Bal, MD, MBA, chairman and chief executive officer of Amedica, said in the release. “We look forward to continued research and future publications to underscore the favorable cell adhesion properties of silicon nitride, which are paramount to rapid bone fusion and improved patient outcomes.”

Reference: